A new day for precision oncology

A new world of NGS

Brought to you by ThermoFisher Scientific

Next-Generation Solution for Genomic Profiling 

The Oncomine Precision Assay on the Ion Torrent Genexus System features a complete next-generation sequencing (NGS) testing workflow. Now every lab can go from specimen to report in a single day, providing a comprehensive genomic profile at a speed never possible before*.

This allows you to deliver NGS results at the same time as other single-gene methods, such as immunohistochemistry (IHC). The hands-off, set-up-and-go workflow makes NGS accessible, even if your lab is new to the technology.

With the lowest sample input requirement of any NGS solution, you can successfully sequence more precious samples—even when tissue is very limited.

View Genexus Webinars

Read the Latest News on the Genexus System

Request Pricing

Ion Torrent Genexus System

Introducing the first turnkey NGS system that automates the specimen-to-report workflow and delivers results in a single day. 

With just 10 minutes of hands-on time and two touchpoints, users can get up and running quickly with significantly less training.  This highly flexible system lets you cost-effectively process samples as they come in - even just one.  

Visit the Genexus System Page

Oncomine Precision Assay

The Oncomine Precision Assay features carefully curated biomarker content spanning 50 genes based on the latest therapy developments, medical guidelines, and clinical trials. Enhanced fusion detection provides broad coverage for the most prevalent isoforms, along with novel fusions. You have the option to profile DNA or RNA from plasma or lysate derived from FFPE samples, giving you a wide range of utility. All of this is provided with a one-day turnaround time and a highly automated workflow on the Genexus System.

Visit the Oncomine Assay Page

Download the Flyer   Download Infographic

Celiac & GRD

Don't let precious samples go untested

Did you know that some NGS send-out labs have test failure rates of 20% due to their high input requirement?1-4 At that rate, 1 out of every 5 samples will not pass due to lack of tissue, and many more are never submitted for testing at all.

Not with Oncomine Solutions. You can experience a sequencing success rate of over 95% because we only require 10ng of nucleic acid input. That means you can get an NGS result for most of the precious samples you have.

Maximize your ability to detect key biomarkers

Curated Pan-Cancer Content

  • Mutation, CNV and fusion variant types across 50 key genes
  • Driver and resistance variants

Fusion Sync Detection

  • Sensitive and specific – targeted isoform designs
  • Novel fusion detection

Molecular Tagging

  • Enhanced low-level variant detection
  • Key for liquid biopsy testing

Tissue and Plasma

  • One test, one workflow, multiple sample types

FusionSyncTM Detection Technology

Gene fusions are an increasingly important target in precision oncology.  Oncomine assays are superior for both sequencing success rate and sensitivity, two critical factors for fusion detection.  Even when the tissue is very limited or the variants exist at low levels in the sample,  you can detect key fusions by combining:

• Targeted known fusion detection

• Non-targeted detection of novel fusion combinations

• Novel fusion detection

Register for The Pathologist Webinar on March 26, 2020 to learn more about FusionSync detection technology  https://thepathologist.com/webinar/hear-both-sides-of-the-fusion-detection-story

Oncomine Reporter 

The Oncomine Reporter delivers clear and concise reports that present all relevant variants with annotated information about targeted therapies, guidelines, and enrollment of ongoing clinical trials.  

The report is customizable so that you can tailor it to fit your team's needs.

Visit the Oncomine Informatics Page

NGS Expert Opinions on the Genexus System 

Dr. Nicola Normanno from Naples and Dr. Philip Jermann from Basel share their opinion on how the new Genexus NGS System can help new laboratories adopt NGS, and also how expert labs can benefit from its speed and simplicity.

Dr. Jose Costa Describes His Experience 

Hear from Dr. Jose Costa of IPATIMUP in Portugal, whose lab was the first to implement the Genexus System. 

Webinar 1 - December 2019

Introducing a New World of NGS: One-Day, Hands-Free Solution to Fit in Any Lab

  • Learn how the Genexus System addresses key challenges to NGS adoption.
  • See the next-generation solution for genomic profiling of cancer samples.
  • Hear about the experience of the first laboratory to implement this solution.


Dr. Jose Costa, IPATIMUP                                                             Dr. Andy Felton, Thermo Fisher Scientific



View Recording 


Webinar 2 - March 2020

Hear Both Sides of the Fusion Detection Story

  • Review three different methods in a comparison study performed and presented by Dr. Wei Song
  • Hear about the principles of and first data generated by a new FusionSync method from Dr. Philip Jermann.


Dr. Wei Song, Weill Cornel Medical College                                   Dr. Philip Jermann, University Hospital Basel



View Recording 


Request a Demonstration

Are you ready to experience the power of the Oncomine Precision Assay on the Genexus System?  Request a demonstration today and our representatives will contact you shortly.


1.  Next-Generation Sequencing in 305 Consecutive Patents: Clinical Outcomes and Management Changes; Gregory J. Kubicek, MD., et al., Journal of Clinical Oncology, Aug. 2019.
2.  J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.
3.  Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer; Jason Zhu, et al.; Urologic Cancer: Seminars and Original Investigations, July 2019.
4.  Abstract 4889: Comparison of tumor mutational burden using the Ion Oncomine™ TML and FoundationOne™ assays with routine clinical FFPE tissue samples to predict durable clinical benefit in lung cancer and melanoma patients - a multivariate analysis integrating PD-L1 and CD8+ evaluation. Heeke S. et al. DOI: 10.1158/1538-7445.AM2019-4889; July 2019.


For Research Use Only.  Not for use in diagnostic procedures.  *Specimen-to-report workflow will be available after the Ion Torrent Genexus Purification System and integrated reporting capabilities are added in 2020.